Sellas Life Sciences is trading 7.7% up at $12.65 as traders reposition ahead of a pivotal survival readout from the Phase 3 REGAL trial.
- The upcoming data for the company’s WT1 immunotherapy program is viewed as a major binary event for the treatment of acute myeloid leukemia.
- The stock has seen significant volatility recently, including a 6% drop on July 16, 2026, driven by speculative interest and social-media-fueled trading activity.